Heart - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys, failed to meet its main goal of helping people to live longer.

AstraZeneca’s trial drug for AL amyloidosis fails to meet survival goal

HQ Team July 16, 2025: AstraZeneca Plc’s investigational drug to treat AL amyloidosis, a rare and serious disease affecting the heart and kidneys,.

by HealthQuill
July 16, 2025
0 Comments

Lupin Limited, an Indian maker of branded, generic formulations, biotechnology products, and active pharmaceutical ingredients, has got USFDA approval for its ANDA injection, glycopyrrolate.

Drugs Pharma

Lupin gets FDA nod for injection to lessen saliva, stomach acid

Lupin Limited, an Indian maker of branded, generic formulations, biotechnology products, and active pharmaceutical ingredients, has got USFDA approval for its ANDA injection,.

by HealthQuill
February 9, 2023
0 Comments

About Us

Contact Info

Follow Us

AstraZeneca’s trial drug for AL amyloidosis fails to meet survival goal

Lupin gets FDA nod for injection to lessen saliva, stomach acid￼

Lupin gets FDA nod for injection to lessen saliva, stomach acid